Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Information for investors
Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
Catching up in Cambridge
We recently joined a full house of attendees at CrownBio’s annual conference.
An interview with Nigel Theobald
Nigel Theobald, CEO of N4 Pharma, has spoken to Dr. Kevin Robinson at Manufacturing Chemist magazine about how the company has developed Nuvec® and the impact it could have for vaccines and cancer treatments.
N4 Pharma in SHARES Magazine
N4 Pharma has been featured in the latest issue of SHARES Magazine.